AMLX: Breakaway Gap detected on 20 Aug 2026

AMLX is forming a breakaway gap pattern following positive Phase 3 LUCIDITY results announced on August 18, 2026, showing avexitide significantly reduced serious hypoglycemic events in post-bariatric hypoglycemia. The stock is trading at $38.60, just 1.2% below the 52-week high of $39.07, with structure, volume, and breakout scores of 15.0, 12.0, and 12.0 respectively (overall score 81.0). Current volume of 8.24M shares represents 2.41x the 20-day average, confirming strong participation. RSI at 85.23 signals overbought conditions, and ATR volatility of 6.58% reflects elevated intraday movement.

Amylyx reported positive Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia and announced a $350 million equity offering, with plans to submit a New Drug Application by late 2026 for this first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies. Cash runway is expected to fund operations into 2028. The company also presented Phase 1 LUMINA trial data for AMX0114, an antisense oligonucleotide for ALS treatment, showing no drug-related serious adverse events. The 108.65% gain over one month and 202.98% gain over three months reflect the market's enthusiasm around the avexitide catalyst and expanded pipeline progress.

A successful breakaway gap breakout would target $40.78 (conservative target), representing a 5.6% move above current price with resistance near $39.07 acting as the near-term ceiling. The pattern requires sustained volume above 3.4M shares (20-day average) to confirm conviction—current volume at 2.41x average provides initial support. Win probability of 56.14% indicates slightly better than even odds. The pattern invalidates below $22.47 (key support), which would represent a 41.8% decline and signal failure of the bullish setup.

RSI at 85.23 indicates extreme overbought conditions, suggesting elevated near-term pullback risk after a 65% one-week surge. The $350 million secondary offering announced on August 18 creates immediate dilution risk and may pressure the stock during pricing and completion. While the NDA submission is planned for late 2026, regulatory approval remains uncertain and the company may need additional capital raises beyond this offering. Beta of 0.37 provides some downside cushion, but biotech stocks are inherently volatile around clinical catalysts. Post-event sell-the-news pressure is typical following major pharmaceutical announcements, particularly with concurrent equity dilution.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.